https://www.thebodypro.com/category/tenofovir-tdf-viread

Tenofovir Disoproxil Fumarate (Viread)

The Latest

Conference Centre at 10th IAS Conference on HIV Science (IAS 2019), Mexico City, Mexico
Conference Coverage

Does Descovy Really Work Better Than Truvada for PrEP? One Researcher Raises Questions About the DISCOVER Trial Results

Newly presented data from IAS 2019 spark discussion about study populations, study endpoints, and potential weight gain.

Christoph D. Spinner
Conference Coverage

DISCOVER PrEP Trial Finds F/TAF Has Superior Load Time and Tail Compared to F/TDF

But given cost concerns, advocates question whether the benefits are enough to warrant dumping F/TDF as the go-to PrEP option.

illustration of person on cliff with arms raised as sun rises/sets
News

This Week in HIV Research: From PrEP to Treatment, There's Always More to Learn

April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects Img
Conference Coverage

TAF as Effective as TDF in Cisgender Women, With Fewer Side Effects

A pooled analysis presented at CROI 2019 showed fewer kidney and bone density issues with tenofovir alafenamide in cisgender women than were found with the older formulation.

Promo Image
News

This Week in HIV Research: The Clinical Impacts of HIV Stigma

Internalized HIV stigma, depression, and adherence in women; what “internalized HIV stigma” actually means; tenofovir-containing gel and genital herpes prevention; the neurocognitive effects of cerebrospinal HIV escape.

Promo Image
News

This Week in HIV Research: Renal Upsides for Tenofovir Alafenamide

E/C/F/TAF viability for dialysis patients; TAF safety following renal damage; mental health needs for American Indians; parenting desires of people with HIV.

Promo Image
News

This Week in HIV Research: A New Frontier in Organ Transplantation

HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.

Promo Image
IDWeek

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin Img
Tuberculosis

Twice-Daily Tenofovir Alafenamide Dose Might Overcome Interaction With Rifampicin

Twice-daily tenofovir alafenamide plus rifampicin provided similar exposures to once-daily TAF in a pharmacokinetic study. This strategy might be a suitable option for people with HIV/TB coinfection.

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study Img
Bone

Tenofovir (TDF) Not Tied to Bone Fractures in French Case-Control Study

The findings could inform the debate on the merits of TDF, which is available in many regions as a less-costly generic, versus the more recently approved prodrug tenofovir alafenamide (TAF).